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ABSTRACT IL-17A is a proinflammatory cytokine
produced by a variety of cells. In the current study, we
examined the role of IL-17A in sepsis induced in mice
by cecal ligation and puncture (CLP). IL-17A levels,
which rose time-dependently in plasma after CLP, were
not affected in the absence of  T cells or neutro-
phils. In sharp contrast,  T cell-knockout or  T
cell-depleted mice displayed baseline IL-17A plasma
levels after CLP. Neutralization of IL-17A by two
different antibodies improved sepsis (survival from
10% to nearly 60%). Unexpectedly, antibody treat-
ment was protective, even when administration of anti-
IL-17A was delayed for up to 12 h after CLP. These
protective effects of IL-17A blockade were associated
with substantially reduced levels of bacteremia together
with significant reductions of systemic proinflammatory
cytokines and chemokines in plasma. In vitro incubation
of mouse peritoneal macrophages with lipopolysaccha-
ride (LPS) in the copresence of IL-17A substantially
increased the production of TNF-, IL-1, and IL-6 by
these cells. These data suggest that, during experimen-
tal sepsis,  T cell-derived IL-17A promotes high levels
of proinflammatory mediators and bacteremia, result-
ing in enhanced lethality. IL-17A may be a potential
therapeutic target in sepsis.—Flierl, M. A., Rittirsch, D.,
Gao, H., Hoesel, L. M., Nadeau, B. A., Day, D. E.,
Zetoune, F. S., Sarma, J. V., Huber-Lang, M. S., Ferrara,
J. L. M., Ward, P. A. Adverse functions of IL-17A in
experimental sepsis. FASEB J. 22, 2198–2205 (2008)
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Despite tremendous scientific and clinical efforts,
sepsis continues to be an incalculable and enigmatic
disease. In fact, the mortality of patients with septic
shock has increased over the past years (1), and septi-
cemia ranks now as the 10th leading cause of death in
the United States, as opposed to 13th in 1990 (2). It is
now becoming apparent that sepsis might not be a
solitary, clearly defined disease, but rather a puzzling
interplay of various biological systems and cascades with
the immune system, resulting in a highly variable
clinical picture. As a result, we are only able to use
crude clinical parameters like body temperature, leu-
kocyte count, heart rate and respiratory rate in an
attempt to define sepsis. Thus, many clinicians refer to
sepsis as a syndrome rather than a disease. In parallel
with the difficulties encountered in the clinical setting,
sepsis research has suffered from many setbacks. In
many cases, promising experimental strategies have
failed to be successful in the clinical setting (3, 4).
Therefore, there is a compelling need to broaden our
comprehension of the pathophysiology of inflamma-
tion and its regulation. Recently, novel mediators of
sepsis and inflammation have been discovered, such as
HMGB-1 (5, 6), putting new promising therapeutical
targets on the murky horizon. Further, the discovery of
the IL-17 cytokine family has provided a new pathway
for crosstalk between adaptive and innate immunity. To
date, several sources of IL-17 have been identified:
Th17 cells, CD8 T cells, natural killer (NK) cells,  T
cells,  T cells, and neutrophils (7). It is now becom-
ing clear that IL-17A (the first described member of the
IL-17 family) is a mediator of neutrophil stimulation
and mobilization by T lymphocytes (8). This presents
IL-17A with a uniquely powerful position at the inter-
face between adaptive and innate immunity. Thus, it is
not surprising that the IL-17 family has been shown to
be involved in various physiological and pathophysio-
logical processes such as granulopoesis, defense against
bacteria, rheumatoid arthritis, allograft rejection, tu-
mor modulation, and asthma and allergic reactions (7,
9–16).
In the current study, we sought to evaluate the role of
IL-17A during experimental sepsis induced by CLP in
mice. Given the proinflammatory effects of IL-17A in
various pathophysiological settings, we hypothesized
that elevated systemic levels of IL-17A during sepsis
might be harmful, connecting the inflammatory arse-
nal of adaptive and innate immunity and ultimately
resulting in the well-described inflammatory downward
1 These authors contributed equally to this work.
2 Correspondence: Department of Pathology, The Univer-
sity of Michigan Medical School, 1301 Catherine Rd., Ann
Arbor, MI 48109-0602, USA. E-mail: pward@umich.edu
doi: 10.1096/fj.07-105221
2198 0892-6638/08/0022-2198 © FASEB
spiral occurring in sepsis. In the setting of experimental
sepsis, we identify  T cells, but not  T cells or
neutrophils, as the source of elevated plasma IL-17A
levels following CLP. Moreover, we describe protective
effects of IL-17A blockade on sepsis mortality, effective
even when carried out up to 12 h after CLP, associated
with reduced blood-borne bacteria (colony forming
units, CFUs) and decreased levels of proinflammatory
cytokines and chemokines. Accordingly, IL-17A may be
a target in human sepsis.
MATERIALS AND METHODS
Animals, anesthesia, and experimental sepsis
All procedures were performed in accordance with the Na-
tional Institutes of Health guidelines and the University
Committee on Use and Care of Animals (UCUCA), University
of Michigan. Specific pathogen-free, male C57BL/6,  T
cell-knockout (B6.129S2-Tcratm1Mom/J) or  T cell-knockout
(B6.129P2-Tcrdtm1Mom/J) mice (9–10 wk of age, 22–25 g;
Jackson Laboratories, Bar Harbor, ME, USA) were used. Both
knockout mice are on a C57BL/6 background. Intraperito-
neal ketamine (100 mg/kg body weight) (Fort Dodge Animal
Health, Fort Dodge, IA, USA) was used for anesthesia and
intraperitoneal xylazine (13 mg/kg body weight) (Bayer
Corp. Shawnee Mission, KS, USA) for sedation. Experimental
sepsis was induced by CLP, as described previously (17). In
short, a 1-cm abdominal midline incision was made; the
cecum was exposed, ligated, and punctured through and
through with a 19-gauge needle; and a small portion of feces
was pressed out to ensure persistence of the punctures. After
repositioning of the bowel, the abdomen was closed in layers
using 6-0 surgical sutures (Ethicon Inc., Somerville, NJ, USA)
and metallic clips. Before and after the surgery, animals had
unrestricted access to food and water.
Plasma collection
At given time points after CLP, whole blood was collected by
cardiac puncture into syringes containing anticoagulant ci-
trate dextrose (ACD; Baxter, Deerfield, IL, USA) in a 9:1
ratio. Samples were centrifuged (3000 rpm, 10 min, 4°C);
plasma was obtained and immediately stored at 80°C until
further analysis.
Cytokine/chemokine measurements
Plasma was harvested as described above. The following
mouse ELISA kits were used: TNF-, IL-1, IL-6, IL-10, MIP-2,
MIP-1, MCP-1, IL-17, TGF (all R&D Systems, Minneapolis,
MN, USA). For quantification of HMGB1, a commercially
available ELISA kit (Shino-Test Corporation, Kanagawa, Ja-
pan) was used. All experiments were performed according to
the manufacturer’s protocol.
 T cell depletion
 T cell depletion was induced using 500-g hamster anti-
mouse TCR  monoclonal antibodies (Biolegend, San Di-
ego, CA, USA) 5 days before CLP, as described previously (18,
19). Control animals received an intraperitoneal injection of
isotype-matched Armenian hamster IgG (500 g; Biolegend,
San Diego, CA, USA).
Anti-IL-17A antibodies
A specific neutralizing monoclonal anti-mouse IL-17A anti-
body was obtained from eBioscience (San Diego, CA, USA)
and a polyclonal anti-mouse IL-17A antibody from R&D
Systems. The monoclonal neutralizing antibody was used in
all experiments, while the polyclonal R&D antibody was
exclusively used to confirm the survival data (data not
shown). Both antibodies have been characterized by the
manufacturers to specifically neutralize mouse IL-17A and
contain 0.001 endotoxin/g protein. For in vivo neutraliz-
ing experiments, 45 g of anti-IL-17A or control IgG (Jackson
ImmunoResearch, West Grove, PA, USA) was administered
intravenously in a total volume of 200 l at the time of CLP.
In some survival studies, infusions of blocking antibodies to
IL-17A were delayed 6 or 12 h after CLP where indicated.
Determination of CFUs in blood
Blood was obtained by cardiac puncture and was drawn into
syringes containing 10% citrate. Following appropriate dilu-
tion in 0.9% saline, 100-l samples were plated in duplicates
on 5% sheep blood agar (Remel, Lenexa, KS, USA) and
incubated for 24 h at 37°C under aerobic conditions. CFUs
were then determined and multiplied by the dilution factor.
Isolation and incubation of murine peritoneal macrophages
Mouse peritoneal macrophages were harvested 5 days after
intraperitoneal injection of 1.5 ml thioglycolate (BD Bio-
sciences, Sparks, MD, USA; 2.4 g/100 ml) by peritoneal
lavage with PBS. After washing, the purity of cell suspension
was 	95% macrophages. Macrophages (5
106 per experi-
mental condition) were allowed to adhere to tissue culture
plates over 2 h and incubated in RPMI medium containing
0.5% BSA for 4 h at 37°C. Recombinant, endotoxin-free
mouse IL-17A was obtained from R&D Systems, and LPS
(Escherichia coli 0111:B4) was purchased from Sigma-Aldrich
(St. Louis, MO, USA).
Statistical analysis
All values are expressed as means  se. Data were analyzed
with a one-way ANOVA, and individual group means were
then compared with a Student-Newman-Keuls test. Differ-
ences were considered significant when P  0.05.
RESULTS
Elevated IL-17A levels during sepsis
Plasma levels of IL-17A as a function of time were
evaluated in mice following CLP. There was a progres-
sive rise in plasma levels of IL-17A, peaking at 12 h after
CLP, followed by a rapid decline to baseline values at
24 h (Fig. 1A).
Systemic IL-17A requires  T cells but not  T
cells or neutrophils
Because IL-17A has been reported to be produced by
 T cells,  T cells, NK cells, CD4 T cells, and
neutrophils (7), we sought to determine the cell pop-
ulation chiefly responsible for the elevated levels of
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IL-17A after CLP. Experimental sepsis was induced by
CLP in wild-type,  T cell-knockout mice (B6.129S2-
Tcratm1Mom/J) or  T cell-knockout mice (B6.129P2-
Tcrdtm1Mom/J), comparing plasma levels of IL-17A 12 h
after CLP to wild-type littermates. As shown in Fig. 1B,
levels of IL-17A were not significantly altered in  T
cell-knockout mice when compared to wild-type litter-
mates. In sharp contrast, there was complete abolition
of systemic IL-17A buildup in septic animals lacking 
T cells (Fig. 1C), suggesting a key role for  T cells in
the sepsis-induced production of systemic IL-17A.
These findings were confirmed in CLP mice depleted
of  T cells using a monoclonal hamster antibody
when compared to isotype IgG-treated mice (Fig.
1D). Neutrophils (PMNs) have been reported to
contain intracellular IL-17A message and protein,
but release of free, soluble IL-17A from PMN has not
been reported (20 –22). In further experiments,
blood PMNs were depleted using a monoclonal anti-
body, Ly-6G. With blood PMNs falling to less than 5%
of normal blood values, there was no significant
reduction in plasma levels of IL-17A after CLP (data
not shown), indicating that during CLP-induced
sepsis, PMNs were not a significant source of IL-17A.
Moreover, CD4 T cell-knockout mice (B6.129S6-Cd4)
or animals that were T cell depleted with a monoclo-
nal antibody targeting CD4 cells (GK1.5) (23)
showed no significant changes in IL-17A levels 12 h
after CLP in comparison to CD4/ mice and isotype
IgG-treated littermates, respectively (data not
shown). These data indicate that  T cells are the
source of IL-17A in the CLP model of experimental
sepsis.
Neutralization of IL-17A in CLP mice treated with
monoclonal anti-IL-17A
To determine the in vivo efficacy of a neutralizing
monoclonal rat IgG antibody to mouse IL-17A, levels of
IL-17A were determined in plasma obtained from ani-
mals treated intravenously with either control IgG or
neutralizing monoclonal anti-IL-17A 12 h after CLP. As
determined by ELISA, mice treated with an isotype
control IgG displayed similar levels as wild-type mice,
while administration of 45 g monoclonal anti-IL-17A
reduced plasma levels of IL-17A to negative control
levels (data not shown).
Improved survival in CLP after anti-IL-17A treatment
To investigate the role of IL-17A in CLP-induced sepsis,
a neutralizing monoclonal antibody to IL-17A (as de-
scribed above) was given intravenously at the time of
CLP or at 6 or 12 h after CLP. Mice treated with an
isotype control IgG, administered at the same time
points, served as a control. As shown in Fig. 2A, control
IgG-treated mice displayed 8% survival by day 7 (bot-
tom line). In contrast, when mice were administered
anti-IL-17A at the time of CLP, survival was 58% at day
7 (top line, Fig. 2A, P0.05). To investigate whether
delayed infusion of anti-IL-17A would still protect in the
setting of CLP, intravenous infusion was delayed until
12 h after CLP, resulting in survivals of 33% (P0.05),
indicating that delayed infusion of anti-IL-17A was still
significantly protecting against CLP-induced sepsis
(middle line, Fig. 2A). Delay of anti-IL-17A infusion
until 6 h after CLP also resulted in an improved survival
Figure 1. Plasma levels of IL-17A after CLP, as determined by ELISA analysis.
A) IL-17A levels as a function of time after CLP. B) Comparison of IL-17A plasma
levels of wild-type (WT) and  T cell-knockout mice at times 0 (neg ctrl, open
bars) and 12 h after CLP (solid bars). C) Evaluation of IL-17A levels in WT and
 T cell-knockout mice at times 0 (neg ctrl, open bars) and 12 h after CLP (solid
bars). D) IL-17A levels of  T cell-depleted animals (after treatment with hamster
mAb to mouse  T cell epitope) and their isotype-matched littermates 12 h after
CLP. All bars are presented as mean  se; n  5–10/group.
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of 40% (P0.05 vs. ctrl IgG-treated animals) (data not
shown). When mice were given a different neutralizing
antibody to IL-17A (polyclonal) at time 0, survival was
62% at day 5, resulting in a similar improvement of
survival (data not shown).
IL-17A blockade reduces bacteremia after CLP
To determine the effects of in vivo blockade of IL-17A
after CLP might be linked to the level of systemic
bacteremia, anticoagulated blood was collected 0–48 h
after CLP by cardiac puncture, and aerobic blood
cultures were obtained using sheep blood agar plates.
After 24 h of incubation at 37°C, CFUs were quantified.
As shown in Fig. 2B, blood CFUs peaked at 24 and 48 h
after CLP. Accordingly, CLP was induced in mice
treated with either anti-IL-17A or control IgG, and
blood samples were obtained 24 h after CLP and plated
for aerobic CFUs. As shown in Fig. 2C, anti-IL-17A-
treated mice displayed a significant reduction in CFUs
when compared to control IgG-treated littermates 24 h
after CLP. These data suggest that, during CLP, IL-17A
reduces the ability of mice to clear blood-borne bacte-
ria and that with its blockade, the levels of bacteremia
are reduced.
 T cell-knockout mice display improved survival
during experimental sepsis
Because we have identified  T cells as the main
source of IL-17A production during experimental sep-
sis (Fig. 1) and because blockade of IL-17A was protec-
tive during CLP (Fig. 2A), we hypothesized that  T
cell-knockout mice might display improved survival
during CLP. As shown in Fig. 2D,  T cell/ mice
exhibited greatly improved survival during CLP-in-
duced experimental sepsis when compared to C57/BL6
wild-type littermates.
IL-17A increases macrophage in vitro production of
proinflammatory cytokines
To evaluate whether elevated levels of IL-17A during
sepsis might also be related to elevated levels of proin-
flammatory cytokines, murine peritoneal macrophages
were obtained and incubated with either LPS (50
ng/ml), IL-17A (10 pg/ml), or a combination of LPS
(50 ng/ml) and increasing doses of IL-17A (1 pg/ml to
10 ng/ml). As shown in Fig. 3, the addition of IL-17A
greatly potentiated the LPS-induced production of
TNF-, IL-1, or IL-6 by 2- to 3-fold in a dose-depen-
dent manner, whereas IL-17A alone (10 pg/ml) only
slightly augmented the baseline proinflammatory me-
diator response. This effect was observed over a wide
range of doses (1 pg to 10 ng). Interestingly, these
effects were exclusively observed for proinflammatory
cytokines but not the proinflammatory chemokines
MCP-1, MIP-1, or MIP2 (data not shown). Collectively,
these findings suggest that, in the copresence of LPS,
IL-17A increases the in vitro production of proinflam-
matory cytokines by macrophages.
Figure 2. A) Survival
curves of CLP mice in-
fused i.v. with 45 g con-
trol IgG (ctrl IgG) treat-
ment or neutralizing
monoclonal anti-IL-17A
at time 0 or 12 h after
CLP. Numbers of mice
used for each condition
are shown in the frame.
B) Bacterial CFUs in
blood as a function of
time after CLP. All bars
are presented as mean 
se ; n  10/group .
C) CFUs in blood 24 h after sham or CLP surgery in mice were treated i.v. at time 0 with either control IgG (ctrl IgG) or
monoclonal anti-IL-17A (both 45 g). CFUs were determined using sheep blood agar under aerobic conditions. n  5.
D) CLP survival curves of  T cell-knockout mice (n12) vs. wild-type littermates (n12).
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Blockade of IL-17A reduces plasma levels of
proinflammatory cytokines and chemokines after CLP
Given these in vitro observations, we sought to deter-
mine whether blockade of IL-17A in CLP mice affected
the levels of inflammatory mediators in plasma. Mice
were randomly assigned to three groups. The first
group was given sham treatment, the second group was
infused with 45 g of IgG immediately after CLP
(control IgG treatment), and a third group was intra-
venously administered 45 g of monoclonal anti-IL-17A
at the time of CLP. Plasma was obtained at time 0
(sham-treated mice) and 24 h after CLP (IgG- or
anti-IL-17A-treated mice), since proinflammatory medi-
ators peak in blood 24 h after CLP (unpublished data).
There were very low or unmeasurable levels of media-
tors in plasma from all sham-treated mice (Fig. 4). In
animals treated with nonspecific IgG, there were sharp
increments in the cytokines TNF-, IL-1, IL-6, and in
the chemokines MIP-1, MIP-2, and MCP-1 in plasma
24 h after CLP (Fig. 4A–C, F–H). Levels of HMGB-1
were also increased after CLP (Fig. 4I). When CLP mice
were infused with anti-IL-17A at time 0, systemic levels
of all proinflammatory mediators were substantially
reduced, suggesting that IL-17A facilitates the systemic
production of proinflammatory cytokines and chemo-
kines and HMGB-1 after CLP. Interestingly, anti-IL-17A
caused increases in levels of the anti-inflammatory
cytokine IL-10 (Fig. 4D) and TGF (Fig. 4E).
DISCUSSION
The IL-17 family is emerging as an important regulator
of the inflammatory response and has become the key
to an expanding understanding of cytokine networks
that coordinate and interlace innate and adaptive im-
munity (7). Lately, a distinct lineage of CD4 T cells,
Th17 cells, has been identified as the main source of
IL-17A and has clearly been the focus of recent re-
search (16, 24–36). However, besides Th17 cells, other
sources of IL-17A have been identified:  T cells,  T
cells (37), NK cells, and neutrophils (7). In a recent
study, patients suffering from trauma, systemic inflam-
matory response syndrome (SIRS), or sepsis syndrome
were found to have a rapid and prolonged activation of
 T cells but not  T cells, suggesting a significant
role for  T cells as early responders during trauma,
SIRS, and sepsis (38). It is now becoming evident that
these cells are key players in bridging the innate and
adaptive early immune responses. In line with the
current study, in which we identified  T cells as the
predominant source of IL-17A during sepsis (Fig. 1C,
D), recent studies reported that resident  T cells
control neutrophil-mediated innate immune responses
via the production of IL-17A (15, 37). After intraperi-
toneal injection of E. coli, the rapid and transient
production of IL-17A was found to mainly originate
from  T cells and assist in recruitment of neutrophils
(15). Collectively, these data suggest that  T cell-
derived IL-17A enhances innate immunity via recruit-
ment of neutrophils. This rapid recruitment of PMNs
by IL-17A seems, in part, to be regulated by enhance-
ment of chemokine gene expression (39). Interest-
ingly, IL-17A and TNF- seemed to act synergistically to
achieve this goal. Although TNF- initiated chemokine
gene transcription through activation of NF-B, IL-17A
extended the half-life of mRNA via activator of NF-B1
protein (Act-1) -dependent mechanisms (39). In the
present study, we have also found synergistic effects of
IL-17A on LPS-induced in vitro activation of peritoneal
macrophages (Fig. 3). The requirement of Act-1 for
IL-17A and IL-17A receptor (IL-17RA) -dependent sig-
naling during the immune response has been con-
firmed in other studies (40, 41). Moreover, IL-17A has
been reported to be a major orchestrator of sustained
neutrophil mobilization and associated activity through
induction of specific cytokines and colony-stimulating
factors in resident lung cells (42).
By incubating cells with LPS in the copresence of
various doses of IL-17A, we attempted to mimic septi-
cemia and elevated IL-17A levels in vitro to investigate
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Figure 3. Incubation of elicited murine peritoneal macrophages (5
106/ml) with HBSS (neg ctrl), LPS (50 ng/ml),
recombinant IL-17A (10 pg/ml), or the combination of LPS (50 ng/ml) and varying doses of recombinant IL-17A for 4 h (37°C)
in vitro. Analysis of cell supernatants for TNF- (A), IL-1 (B), and IL-6 (C) by ELISA. All bars are presented as mean  se;
n  5/group.
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whether macrophage production of cytokines and che-
mokines can be altered by exposure to IL-17A and LPS.
Interestingly, the copresence of IL-17A with LPS syner-
gistically increased levels of the proinflammatory cyto-
kines TNF-, IL-1, and IL-6 (Fig. 3), whereas levels of
MCP-1, MIP-1, and MIP-2 were not found to be
increased under similar conditions. The exact molecu-
lar mechanism of this observation remains to be deter-
mined, but the data would suggest that IL-17A pro-
duced during sepsis can be implicated in the “cytokine
storm,” which connotes an unregulated development
of inflammatory response.
IL-17A has been found to be elevated in a variety of
inflammatory conditions, such as rheumatoid arthritis,
pneumonia, systemic lupus erythematosus, allograft
rejection, etc. (43, 44) Thus, it is not surprising that
IL-17A acts on various cells, including neutrophils,
fibroblasts, epithelial cells, and endothelial cells, induc-
ing the expression of proinflammatory mediators such
as IL-6, CXC chemokines, and matrix metalloprotein-
ases (43). In the current study, we found reduced levels
of proinflammatory cytokines and chemokines in septic
animals treated with anti-IL-17A when compared to
control IgG-treated littermates (Fig. 4) and that  T
cells were the major source of sepsis-associated in-
creased IL-17A levels (Fig. 1). Chung et al. (45) recently
reported decreased concentrations of TNF-, IL-6, and
IL-12 in  T cell-knockout animals during sepsis. It is
tempting to speculate whether these decreased levels of
proinflammatory mediators are in fact due to the
absence of IL-17A in  T cell-knockout mice or  T
cell-depleted animals during sepsis (Fig. 1C, D), as
IL-17A significantly potentiates the inflammatory medi-
ator production in macrophages in vitro (Fig. 3). Col-
lectively, the data in the current report suggest that
CLP causes increased levels of IL-17A in plasma, which
enhances production of proinflammatory cytokines.
The mechanism by which IL-17A causes enhanced
levels of CFUs in blood after CLP is unclear, but it may
be that the bactericidal function of blood neutrophils is
in some manner compromised under such conditions.
An analogous situation in sepsis has been shown to be
related to uncontrolled generation of C5a, which par-
alyzes MAPK signaling pathways in neutrophils (46).
The unique position of IL-17A at the interface be-
tween innate and acquired immunity puts this mediator
Figure 4. Effects of IL-17A blockade on appearance of cytokines and chemokines in plasma 24 h after CLP, using ELISA:
A) TNF; B) IL-1; C) IL-6; D) IL-10; E) TGF; F) MIP-1; G) MIP-2; H) MCP-1; I) HMGB1. Plasma samples were obtained by
cardiac puncture from sham-treated mice or CLP mice treated with 45 g control IgG (gray bars) or monoclonal anti-IL-17A
(black bars; both administered at the time of CLP). All bars are presented as mean  se; n  5/group.
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in the lead as a crucial signal for the reinforcement and
crosstalk of host defense systems. Thus, IL-17A might
constitute a useful target for therapeutic intervention
in sepsis and other inflammatory settings.
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